Mark Zitter, MBA

Recent increases in the number of therapies indicated for a given oncology subtype has resulted in heightened utilization management stringency.

There is increased interest in the question of whether pharmacoeconomic studies that measure the value of drug therapies affect clinical decisions and payer policies.